CD44 and breast cancer: FACs analysis demonstrated increased CD44+/CD24− CSCs in wild-type ALG3-overexpressing breast cancer cell lines; however, this population was severely diminished upon ALG3 knockdown (control MDA MB-231 TNBC cells were 75.3% CD44+/CD24−, while ALG3 knockdown MDA MB-231 cells were only 42.1% CD44+/CD24−), highlighting that ALG3 may serve as a potential target to decrease radioresistance in breast cancer [79].